Navigation Links
Arpida Announces Full Year 2008 Financial Results
Date:2/25/2009

REINACH, Switzerland, February 25 /PRNewswire-FirstCall/ -- Arpida Ltd (SIX: ARPN) announced today its financial results for the year ending 31 December 2008.

    2008 Key Events

      - Setback in regulatory process for intravenous iclaprim in US
      - Restructuring and focus on iclaprim
      - Top-line results of "intravenous-to-oral" Phase II trial with oral
        iclaprim
      - Leadership change
      - Share placing

    Cash and financial investments of CHF 38.7 million at 31 December 2008

    Post-Year-End Event

      - January 2009: FDA issues Complete Response Letter

    2009 Priorities

      - Finalise restructuring
      - Design a roadmap for approval of intravenous iclaprim
      - Consider and develop strategic options

Dr Jurgen Raths, President and CEO, commented: "The negative FDA response of last January was a serious blow to our company and all of its stakeholders. The steps we have announced and executed, though painful, were unavoidable. We are currently pursuing several strategies to maximise shareholder value. This includes partnering, mergers and acquisitions as well as the disposal of certain assets as we do not have the money nor the time required to further develop iclaprim on our own."

CFO Harry Welten, MBA, added: "Our cash balance at year-end 2008 was in line with our earlier guidance. We maintain our forecast that cash and financial investments will amount to approximately CHF 17 million at year-end 2009."

    Financial review for twelve months to 31 December 2008

    Key financial indicators


    CHF million                        2008    2007

    Research and development expenses (43.8)  (45.0)
    Management and general expenses   (13.4)  (15.4)
    Restructuring expenses            (12.6)      -
    Total operating expenses          (69.9)  (60.4)
    Net result                        (66.5)  (59.1)

   
'/>"/>
SOURCE Arpida Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... DE (PRWEB) January 22, 2015 Controlled ... Pistoia Alliance, which helps companies check the legal requirements ... to expand to China. , As their international ... are globally adopting software solutions built as a result ...
(Date:1/22/2015)... BRUNSWICK , Nueva Jersey , 22 de ... Award for Biomedical Research abre hoy su llamada a ... personas cuya investigación científica ha hecho, o tiene el ... la salud humana. Las nominaciones se aceptarán hasta el ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014  United Therapeutics ... Medtronic, Inc. (NYSE: MDT ) has submitted ... Drug Administration (FDA) for the use of Medtronic,s SynchroMed ... newly developed catheter) for use with United Therapeutics, Remodulin ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... BOSTON, June 18 PAREXEL International,Corporation (Nasdaq: ... announced that it will provide a live webcast ... from 8:30 a.m. to 12:30 p.m.,(EDT)., All ... and Chief,Executive Officer Josef von Rickenbach, Chief Financial ...
... a,global point-of-care diagnostic test manufacturer and wholly owned,subsidiary ... today announced,that its HemoCue Albumin 201 System is ... and monitoring microalbuminuria to be,granted a CLIA waiver ... With,the FDA CLIA waiver, non-laboratory trained physicians and ...
... Symbol: MS, EDMONTON, June 18 /PRNewswire-FirstCall/ - BioMS ... of multiple sclerosis (MS), today,announced that Mr. Kevin Giese, ... Healthcare Conference in New York., WHEN: ... WHERE: Mandarin Oriental, New York, About the ...
Cached Biology Technology:Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 2008 2HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 2HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 4HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 5BioMS Medical to present at Jefferies Healthcare Conference 2
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
(Date:1/22/2015)... Jan. 22, 2015   EyeLock, Inc. , a market leader ... Steve Gerber to the new role of Senior ... for leading development of mobile platforms and wearable solutions for ... and innovation in the semiconductor industry to his role at ...
(Date:12/22/2014)...  NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" ... growing mobile commerce market, announces it has retained famous pickpocket, ... 2015 International CES debut of the Wocket™ biometric smart wallet.  ... the NXT-ID booth January 6th and 7 th , 2015, ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... of Granada researcher has been awarded the Best Film of ... conference of computed microtomography recently celebrated in Brussels, Belgium. Professor ... awarded for his biofilm titled Micro-CT anatomical study of a ... Dryops . This film shows from the inside the anatomy ...
... (SACRAMENTO, Calif.) New research from UC Davis and ... launch a cellular chain of events that leads to ... conduct electrochemical signals between neurons and disrupts normal ... "Dendrite growth and branching during early development is a ...
... diagnosed with prostate cancer during his lifetime, the second leading ... It,s a serious problem and current diagnostic tests aren,t very ... Florida NanoScience Technology Center has found a more accurate test ... but also how aggressive it is. "That,s really what ...
Cached Biology News:Spanish researcher releases a video showing a beetle from the inside 2Research shows how PCBs promote dendrite growth, may increase autism risk 2Research shows how PCBs promote dendrite growth, may increase autism risk 3New diagnostic tool determines aggressiveness of prostate cancer 2New diagnostic tool determines aggressiveness of prostate cancer 3
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
... is involved in translation initiation. PHAS-II is ... bind to eIF-4E, the mRNA cap-binding protein, ... vitro and in cells. Phosphorylation in the ... This allows eIF-4E to bind to eIF-4G ...
... An antibody made to the C-terminal VMAT2 ... kDa in postnuclear supernatants of CHO transfected ... cells (2). Some additional bands, both higher ... and remain unaffected by the inclusion of ...
... Metalloproteinase-2, Hinge Region By immunoblotting the antibody ... It reacts with free MMP-2 or MMP-2 ... buffered aqueous glycerol solution Solution in ... containing 50% glycerol and 15 mM sodium ...
Biology Products: